JPRN-jRCTs051180042招募中2 期
Phase 2 study of gemcitabine and docetaxel chemotherapy for advanced bone and soft tissue sarcomas - GD therapy for advanced sarcomas
Hara Hitomi0 个研究点目标入组 20 人开始时间: 2019年1月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 10age old 至 <= 70age 11month 4weeks old(—)
- 性别
- All
入选标准
- •1)Patients are histopathologically diagnosed as the primary malignant tumor (sarcoma) of bone and soft tissue.
- •2)Patients with advanced bone and soft tissue sarcoma having recurrence or metastasis.
- •3)Patients who have previously received a standard therapy for bone and soft tissue sarcoma or could not receive a standard therapy.
- •4)Patients who aged 10 to 70 years old at the time of enrollment.
- •5)Patients who have a measurable evaluation lesion.
- •6)Performance status (PS) is 0 or 1 in a standard of ECOG.
- •7)Patients who have a primary tumor that appeared in extremity or trunk.
- •8)Laboratory data within 14 days prior to enrollment meet all of the followings:
- •1.Neutrophil more than 1,500 /mm3
- •2.Hemoglobin more than 8.0 g/dL (there is no blood transfusion within 14 days)
- •3.Platelet more than 100,000/mm3
- •4.Total bilirubin less than 1.5 mg/dL
- •5.AST(GOT) less than 100IU/L
- •6.ALT(GPT) less than 100IU/L
- •7.Creatinine less than 1.5 mg/dL
- •8.Creatinine clearance (eGFR) more than 60 mL/min
- •9)normal electrocardiogram within 28 days prior to enrollment
- •10)Patients without interstitial pneumonia, pulmonary fibrosis, pulmonary emphysema.
- •11)Patients were given a written explanation of the study protocol and provided their written informed consent.
排除标准
- •1)Active double cancers within 5 years(cured intraepithelial carcinoma and intramucosal carcinoma are not included)
- •2)Cases with complications of severe infection
- •3) Patients who have hypersensitivity to study drugs
- •4) Patients who have hypersensitivity to polysorbate 80
- •5) Body temperature more than 38 degree
- •6) Pregnant or breastfeeding women
- •7) Severe psychological disease
- •8) Patients who receive the continuous whole body dosage (or intravenous internal use) of steroid or other immunosuppressant
- •9) Unstable angina (within 3 months after onset) , myocardial infarction
- •10) Difficult-to-control hypertension
- •11) Difficult-to-control diabetes
- •12) HBs antigen is positive
- •13) Judgment to attending physician
研究者
相似试验
招募中
2 期
Phase 2 study of gemcitabine and docetaxel chemotherapy for advanced bone and soft tissue sarcomasadvanced bone and soft tissue sarcomasJPRN-UMIN000031004Kobe University20
进行中(未招募)
不适用
Phase II study with gemcitabine/docetaxel first line in women with metastatic breast cancer - SF- 2Gem/taxoncological patients onlyMedDRA version: 6.1Level: PTClassification code 10055113EUCTR2005-006168-71-ITA.S.L. 270
进行中(未招募)
1 期
A fase I/II trial with docetaxel and gemcitabine in hormone refractory prostate cancerHormone fractory prostate cancerEUCTR2004-002353-31-DKOrganisation name was not entered60
招募中
2 期
Study of gemcitabine docetaxel in synovial sarcoma in relapsed metastatic settingCTRI/2020/02/023612Department of Medical Oncology
进行中(未招募)
不适用
Phase II study with gemcitabine/docetaxel fist line in women with metastatic breast cancer. - SF2gem/taxOncologic patients only.MedDRA version: 6.1Level: PTClassification code 10055113EUCTR2006-000165-10-ITA.S.L. 2 SAVONA70
